PURPOSE: To provide a feasible solution to the problem of failed @entity726 surgery. The aim was to evaluate the efficacy and safety of the additional effects of a combined surgical approach. This approach augments the application of trabeculectomy with @entity1138 ( @entity1139 ) by adding subconjunctival bevacizumab injection. The results were compared with those of trabeculectomy with only adjunctive @entity1139 . METHODS: A randomized controlled prospective clinical trial included 28 eyes diagnosed with failed scarred @entity4530 of a previous trabeculectomy. The eyes were divided into two equal groups: combined group A, "trabeculectomy with adjunctive @entity1139 and subconjunctival bevacizumab," and control group B, "trabeculectomy with adjunctive @entity1139 only." The main outcome results included the cumulative probability of surgical success, intraocular pressure (IOP) values, and number of IOP-lowering medications needed to achieve the target IOP. RESULTS: Group A achieved a cumulative probability of complete success of 0.769 and of qualified success of 0.231 at the end of the 24 month study period; group B achieved cumulative probabilities of 0.538 and 0.308, respectively. Group A achieved a lower mean IOP value than group B, with fewer antiglaucoma drugs at all postoperative visits, but this lower value did not reach a statistically significant level (P>0.05). There was no statistically significant difference between both groups regarding best corrected visual acuity, visual field parameters, @entity260 , and additional interventions. No significant adverse effects were caused by this combined approach. CONCLUSION: Bevacizumab was not found to add much to the favorable long-term outcome of conventional trabeculectomy with @entity1139 as a solution to the problem of scarred failed @entity4530 .

Subconjunctival bevacizumab to augment trabeculectomy with XXXX in the management of failed @entity726 surgery.

@entity4530 :: ('MESH:D001768', 'Disease') :: ['bleb'] @entity1138 :: ('MESH:D016685', 'Chemical') :: ['mitomycin C'] @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma'] @entity260 :: ('MESH:D011183', 'Disease') :: ['operative and/or postoperative complications'] @entity1139 :: ('CHEBI:27504', 'Chemical') :: ['MMC']
@entity1138 :: (MESH:D016685,Chemical) :: ['mitomycin C']
